MDWD $1.22 --FDA Decision in 16 days ..Cheap and well financed biotech with huge upside Market Cap $51 million / Cash Balance $34.5 million additional 7.5 million milestone payment expected upon FDA approval NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023 $30.5 million in gross proceeds raised; operating cash runway through 2025